Abametapir is formulated with benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants. Use of the formulated product is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption.
- TRADE NAME: Xeglyze (Dr Reddy's Laboratories)
- INDICATIONS: Topical treatment of head lice infestation
- CLASS: Metalloproteinase inhibitor, Pediculocide
- HALF-LIFE: 71 ± 40 hours (data for a metabolite)
- FDA APPROVAL DATE: 07/24/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4, CYP2B6, CYP1A2 substrates - PREGNANCY: No available data
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
